Clinical Approach to the Therapy of Asthma-COPD Overlap

Overview

Journal Chest

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2018 Aug 6

PMID 30077690

Citations 21

Authors

Diego J Maselli

Megan Hardin

Stephanie A Christenson

Nicola A Hanania

Craig P Hersh

Sandra G Adams

Antonio Anzueto

Jay I Peters

MeiLan K Han

Fernando J Martinez

Affiliations

Soon will be listed here.

Abstract

Over the last few years, there has been a renewed interest in patients with characteristics of both asthma and COPD. Although the precise definition of asthma-COPD overlap (ACO) is still controversial, patients with overlapping features are frequently encountered in clinical practice, and may indeed have worse clinical outcomes and increased health-care utilization than those with asthma or COPD. Therefore, there is a critical need to set a framework for the therapeutic approach of such patients. There are key distinctions in the therapy between asthma and COPD, particularly regarding the initial choice of therapy. However, there is considerable overlap in the use of existing medications for both diseases. Furthermore, novel therapies approved for asthma, such as monoclonal antibodies, may have a role in patients with COPD and ACO. The use of biomarkers, such as peripheral blood eosinophils, exhaled nitric oxide, and serum IgE, may help in selecting appropriate therapies for ACO. In this review, we provide an overview of available treatments for both asthma and COPD and explore their potential role in the treatment of patients with ACO.

Citing Articles

Phenotyping asthma with airflow obstruction in middle-aged and older adults: a CADSET clinical research collaboration.

Bertels X, Edris A, Garcia-Aymerich J, Faner R, Meteran H, Sigsgaard T BMJ Open Respir Res. 2023; 10(1).

PMID: 37612099 PMC: 10450061. DOI: 10.1136/bmjresp-2023-001760.

Effects of a Peptide Derived from the Primary Sequence of a Kallikrein Inhibitor Isolated from (pep-BbKI) in an Asthma-COPD Overlap (ACO) Model.

da Silva L, Barbosa J, Joao J, Fukuzaki S, do Nascimento Camargo L, Dos Santos T Int J Mol Sci. 2023; 24(14).

PMID: 37511021 PMC: 10379932. DOI: 10.3390/ijms241411261.

COPD Patients with Asthma Features in Vietnam: Prevalence and Suitability for Personalized Medicine.

Van Tho N, Phan T, Dinh-Xuan A, Ngo Q, Lan L J Pers Med. 2023; 13(6).

PMID: 37373890 PMC: 10302634. DOI: 10.3390/jpm13060901.

Current Perspectives of Pharmacotherapies for COPD.

Pleasants R, Donohue J Respir Care. 2023; 68(7):927-938.

PMID: 37353337 PMC: 10289617. DOI: 10.4187/respcare.10952.

Discriminative Accuracy of the CAPTURE Tool for Identifying Chronic Obstructive Pulmonary Disease in US Primary Care Settings.

Martinez F, Han M, Lopez C, Murray S, Mannino D, Anderson S JAMA. 2023; 329(6):490-501.

PMID: 36786790 PMC: 9929696. DOI: 10.1001/jama.2023.0128.

References

Tashkin D, Chipps B, Trudo F, Zangrilli J . Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses. J Asthma. 2014; 51(6):603-9. PMC: 4162502. DOI: 10.3109/02770903.2014.895012. View

Simpson J, Powell H, Boyle M, Scott R, Gibson P . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2007; 177(2):148-55. DOI: 10.1164/rccm.200707-1134OC. View

Chung K, Wenzel S, Brozek J, Bush A, Castro M, Sterk P . International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2013; 43(2):343-73. DOI: 10.1183/09031936.00202013. View

Brightling C, Bleecker E, Panettieri Jr R, Bafadhel M, She D, Ward C . Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014; 2(11):891-901. PMC: 5082845. DOI: 10.1016/S2213-2600(14)70187-0. View

Pavord I, Chanez P, Criner G, Kerstjens H, Korn S, Lugogo N . Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017; 377(17):1613-1629. DOI: 10.1056/NEJMoa1708208. View

Pavord I, Lettis S, Locantore N, Pascoe S, Jones P, Wedzicha J . Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2015; 71(2):118-25. PMC: 4752631. DOI: 10.1136/thoraxjnl-2015-207021. View

de Marco R, Pesce G, Marcon A, Accordini S, Antonicelli L, Bugiani M . The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One. 2013; 8(5):e62985. PMC: 3651288. DOI: 10.1371/journal.pone.0062985. View

Hole O, Winther F, Straume B . Clinical research: the influence of the pharmaceutical industry. Eur J Clin Pharmacol. 2001; 56(11):851-3. DOI: 10.1007/s002280000238. View

Bateman E, Reddel H, van Zyl-Smit R, Agusti A . The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?. Lancet Respir Med. 2015; 3(9):719-728. DOI: 10.1016/S2213-2600(15)00254-4. View

10.

Watz H, Tetzlaff K, Wouters E, Kirsten A, Magnussen H, Rodriguez-Roisin R . Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016; 4(5):390-8. DOI: 10.1016/S2213-2600(16)00100-4. View

11.

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15):1543-54. DOI: 10.1056/NEJMoa0805800. View

12.

Cosentino J, Zhao H, Hardin M, Hersh C, Crapo J, Kim V . Analysis of Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Defined on the Basis of Bronchodilator Response and Degree of Emphysema. Ann Am Thorac Soc. 2016; 13(9):1483-9. PMC: 5614769. DOI: 10.1513/AnnalsATS.201511-761OC. View

13.

Kew K, Undela K, Kotortsi I, Ferrara G . Macrolides for chronic asthma. Cochrane Database Syst Rev. 2015; (9):CD002997. DOI: 10.1002/14651858.CD002997.pub4. View

14.

Pascoe S, Locantore N, Dransfield M, Barnes N, Pavord I . Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015; 3(6):435-42. DOI: 10.1016/S2213-2600(15)00106-X. View

15.

Rodrigo G, Castro-Rodriguez J . What is the role of tiotropium in asthma?: a systematic review with meta-analysis. Chest. 2014; 147(2):388-396. DOI: 10.1378/chest.14-1698. View

16.

Singh D, Kolsum U, Brightling C, Locantore N, Agusti A, Tal-Singer R . Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014; 44(6):1697-700. DOI: 10.1183/09031936.00162414. View

17.

Calverley P, Anderson J, Brook R, Crim C, Gallot N, Kilbride S . Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. Am J Respir Crit Care Med. 2017; 197(1):47-55. DOI: 10.1164/rccm.201610-2086OC. View

18.

Kerstjens H, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M . Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012; 367(13):1198-207. DOI: 10.1056/NEJMoa1208606. View

19.

Maltby S, Gibson P, Powell H, McDonald V . Omalizumab Treatment Response in a Population With Severe Allergic Asthma and Overlapping COPD. Chest. 2016; 151(1):78-89. DOI: 10.1016/j.chest.2016.09.035. View

20.

Brusselle G, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V . Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013; 68(4):322-9. DOI: 10.1136/thoraxjnl-2012-202698. View